EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Cardiovascular aspects of ELABELA: A potential diagnostic biomarker and therapeutic target

Chuanming Xu

Vascular Pharmacology · 2023-08 · 151 · 107193

DOI: 10.1016/j.vph.2023.107193 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Vascular Pharmacology, 2023-08. Verfasst von Chuanming Xu. Beteiligte Einrichtung: Translational Medicine Centre, Jiangxi University of Chinese Medicine, Nanchang 330002, Jiangxi, China. Electronic address: chuanming.xu@jxutcm.edu.c…. Hauptthemen laut MEDLINE: Peptide Hormones, Cardiovascular System, Cardiovascular Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 114 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Health Commission of Jiangxi Province, Guangxi University of Chinese Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ELABELA, an early endogenous ligand for the G protein-coupled receptor APJ (apelin peptide jejunum, apelin receptor), has been known as an important regulator in cardiovascular homeostasis and may be a novel therapeutic target for multiple cardiovascular diseases (CVDs). At the physiological level, ELABELA exhibits angiogenic and vasorelaxant effects and is essential for heart development. At the pathological level, circulating ELABELA levels may be a novel diagnostic biomarker for various CVDs. ELABELA peripherally displays antihypertensive, vascular-protective, and cardioprotective effects, whereas central administration of ELABELA elevated BP and caused cardiovascular remodeling. This review highlights the physiological and pathological roles of ELABELA in the cardiovascular system. Enhancement of the peripheral ELABELA may be a promising pharmacological therapeutic strategy for CVDs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peptide HormonesCardiovascular SystemCardiovascular DiseasesHumansHeartApelin ReceptorsBiomarkers

Stichwörter der Autor:innen

ELABELAHeart diseasesHypertensionVascular diseases

Substanzen

Peptide HormonesApelin ReceptorsBiomarkers

Autor:innen und Institutionen

  • Translational Medicine Centre, Jiangxi University of Chinese Medicine, Nanchang 330002, Jiangxi, China. Electronic address: chuanming.xu@jxutcm.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Health Commission of Jiangxi Province
  • Guangxi University of Chinese Medicine
  • Natural Science Foundation of Jiangxi Province
  • Key Science and Technology Research Project in Jiangxi Province Department of Education

Zitieren

APA

Xu, C. (2023). Cardiovascular aspects of ELABELA: A potential diagnostic biomarker and therapeutic target. Vascular Pharmacology, 151, 107193. https://doi.org/10.1016/j.vph.2023.107193

Vancouver

Xu C. Cardiovascular aspects of ELABELA: A potential diagnostic biomarker and therapeutic target. Vascular Pharmacology. 2023;151:107193. doi:10.1016/j.vph.2023.107193

BibTeX
@article{Xu2023,
  author = {Xu, Chuanming},
  title = {Cardiovascular aspects of ELABELA: A potential diagnostic biomarker and therapeutic target},
  journal = {Vascular Pharmacology},
  year = {2023},
  volume = {151},
  pages = {107193},
  doi = {10.1016/j.vph.2023.107193}
}
Kostenlos starten →